Paul Tudor Jones’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Paul Tudor Jones’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-49,297	Closed	-$132K	–	3032
2023 Q1	$132K	Sell	49,297 -63,449	-56%	-$305K	﹤0.01%	2235
2022 Q4	$612K	Buy	112,746 +28,627	+34%	+$240K	0.01%	1450
2022 Q3	$1.05M	Buy	84,119 +39,155	+87%	+$447K	0.02%	880
2022 Q2	$222K	Buy	+44,964	New	+$249K	0.01%	1757
2021 Q1	–	Sell	-32,607	Closed	-$587K	–	1914
2020 Q4	$587K	Buy	32,607 +5,875	+22%	+$87.8K	0.02%	889
2020 Q3	$309K	Buy	+26,732	New	+$441K	0.01%	974
2018 Q4	–	Sell	-5,227	Closed	-$273K	–	1269
2018 Q3	$273K	Buy	+5,227	New	+$285K	0.01%	889

Other funds holding GTHX

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's GTHX Position: Q2 2023 in Review

Paul Tudor Jones sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2023, closing a stake of 49,297 shares — an estimated $132K sold.

Paul Tudor Jones first reported a position in GTHX in Q3 2018 and held it in 7 quarters. The position peaked at $1.05M in Q3 2022. 80 funds tracked by Wall St. Rank hold GTHX as of Q2 2023.

Paul Tudor Jones reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Paul Tudor Jones sold 49,297 G1 Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $132K.
Paul Tudor Jones first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 7 quarters.
Paul Tudor Jones's G1 Therapeutics, Inc. Common Stock position peaked at $1.05M in Q3 2022.
80 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Tudor Investment Corp's 13F filing for Q2 2023, filed 14 Aug 2023.